ATE392904T1 - Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid - Google Patents

Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid

Info

Publication number
ATE392904T1
ATE392904T1 AT01903625T AT01903625T ATE392904T1 AT E392904 T1 ATE392904 T1 AT E392904T1 AT 01903625 T AT01903625 T AT 01903625T AT 01903625 T AT01903625 T AT 01903625T AT E392904 T1 ATE392904 T1 AT E392904T1
Authority
AT
Austria
Prior art keywords
oligodesoxynucleotide
immuno
immunogenic
adjuvants
stimulation
Prior art date
Application number
AT01903625T
Other languages
English (en)
Inventor
Karen Lingnau
Frank Mattner
Walter Schmidt
Max Birnstiel
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE392904T1 publication Critical patent/ATE392904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT01903625T 2000-01-28 2001-01-05 Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid ATE392904T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0012900A AT409085B (de) 2000-01-28 2000-01-28 Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
PCT/EP2001/000087 WO2001054720A1 (en) 2000-01-28 2001-01-05 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants

Publications (1)

Publication Number Publication Date
ATE392904T1 true ATE392904T1 (de) 2008-05-15

Family

ID=3635970

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0012900A AT409085B (de) 2000-01-28 2000-01-28 Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT01903625T ATE392904T1 (de) 2000-01-28 2001-01-05 Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0012900A AT409085B (de) 2000-01-28 2000-01-28 Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen

Country Status (12)

Country Link
US (1) US20020197269A1 (de)
EP (1) EP1251871B1 (de)
JP (1) JP2003520824A (de)
AR (1) AR026940A1 (de)
AT (2) AT409085B (de)
AU (1) AU784403B2 (de)
CA (1) CA2396884A1 (de)
DE (1) DE60133717T2 (de)
ES (1) ES2304376T3 (de)
PE (1) PE20011217A1 (de)
UY (1) UY26555A1 (de)
WO (1) WO2001054720A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
EP1364010B1 (de) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US20040081655A1 (en) * 2001-01-05 2004-04-29 Karen Lingnau Methods and compositions comprising polycationic compounds
EP1347775B1 (de) 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
KR100985457B1 (ko) 2001-06-21 2010-10-06 다이나박스 테크놀로지 코퍼레이션 키메라 면역조절 화합물 및 그것들의 사용 방법
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002326561B2 (en) 2001-08-07 2008-04-03 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1450856B1 (de) * 2001-09-14 2009-11-11 Cytos Biotechnology AG VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
AU2002360278A1 (en) * 2001-10-12 2003-11-11 Coley Pharmaceutical Gmbh Methods and products for enhancing immune responses using imidazoquinoline compounds
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ATE489969T1 (de) * 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
DK1992635T3 (da) 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
CN1756843B (zh) 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
EP1629005A2 (de) 2003-05-30 2006-03-01 Intercell AG Antigene aus enterococcus
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
EP2292647A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2289906A1 (de) 2006-09-15 2011-03-02 Intercell AG Borrelia-Antigene
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
CN101611048B (zh) 2006-12-12 2012-11-07 赛托斯生物技术公司 含有高浓度鸟嘌呤单体的寡核苷酸
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2158211B1 (de) 2007-05-31 2016-08-10 Medigene AG Mutiertes strukturprotein eines parvovirus
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2511291A3 (de) 2007-06-18 2012-11-07 Intercell AG Chlamydia-Antigene
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
DE102007044093A1 (de) * 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
US9441013B2 (en) 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2809354B1 (de) * 2012-01-31 2021-04-14 CureVac AG Negativ geladene nukleinsäure mit komplexen zur immunstimulation
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
CN112074295A (zh) 2018-02-16 2020-12-11 2A制药公司 用于治疗自身免疫性疾病的细小病毒结构蛋白
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
JP2001526688A (ja) * 1997-05-19 2001-12-18 メルク エンド カンパニー インコーポレーテッド オリゴヌクレオチドアジュバント
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine

Also Published As

Publication number Publication date
DE60133717T2 (de) 2009-07-02
AT409085B (de) 2002-05-27
AU784403B2 (en) 2006-03-30
DE60133717D1 (de) 2008-06-05
ES2304376T3 (es) 2008-10-16
AR026940A1 (es) 2003-03-05
EP1251871B1 (de) 2008-04-23
ATA1292000A (de) 2001-10-15
AU3166501A (en) 2001-08-07
PE20011217A1 (es) 2001-12-04
WO2001054720A1 (en) 2001-08-02
US20020197269A1 (en) 2002-12-26
CA2396884A1 (en) 2001-08-02
EP1251871A1 (de) 2002-10-30
UY26555A1 (es) 2001-08-27
JP2003520824A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
DE60133717D1 (de) Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid
US8277815B2 (en) Pharmaceutical composition comprising an antigen
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
HUP0004327A3 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
JP2003500040A5 (de)
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
GB0105877D0 (en) Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and otherinfecti
IL98845A0 (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
ATE287957T1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
KR960703619A (ko) 백신 조성물(vaccine compositions)
WO2006071896A3 (en) Epitope-based sars vaccine
AU2016201589B2 (en) Peptide adjuvants
EP1283717A4 (de) Rekombinanter leukotoxinimpfstoff aus fusobacterium necrophorum und dessen präparation
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
RU2004117075A (ru) Антигенные матрицы для лечения заболевания костей
WO2002048175A3 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
WO2000062817A3 (en) Inducible vaccines
FR2685333B1 (fr) Nouveau peptide notamment pour la realisation de conjugues immunogenes anti-lhrh, vaccins les incorporant et ensemble de vaccination y relatif.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties